Related Experiment Video
Updated: Jul 7, 2026
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Small Molecules, Big Impact: Structural Innovations Driving PD-L1 Checkpoint Modulation
Salma A Haggag1, Mohammad Abdel-Halim1, Ashraf H Abadi1
1Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt.
Abstract:
Cancer immunotherapy enhances the body's ability to recognize and eliminate tumor cells, mainly by modulating immune checkpoints such as PD-1/PD-L1 and CTLA-4. Monoclonal antibody inhibitors targeting PD-1 or PD-L1 have transformed cancer care, but their high cost, IV administration, and immune-related toxicities have encouraged the development of small-molecule alternatives. Early PD-L1 small-molecule inhibitors, pioneered by Bristol Myers Squibb, block PD-1/PD-L1 interactions by occupying hydrophobic pockets on PD-L1, and SAR studies continue to refine their potency and selectivity. This review focuses on how the structural scaffolds of small-molecule PD-L1 inhibitors determine their mechanisms of action, protein interactions, and biological performance. We examine how different chemotypes influence dimerization of PD-L1, disruption of PD-1 binding, or engagement of additional immune-modulatory pathways. Special attention is given to scaffolds capable of acting through more than one mechanism, as these may offer broader or more durable immunomodulatory effects. We also compare how scaffold design correlates with activity across in vitro assays, co-culture immune models, and in vivo tumor systems, highlighting the physicochemical features that enable or limit translatability. Finally, we discuss emerging clinical efforts, the challenges underlying trial failures, and how refined structural design may guide the next generation of small-molecule PD-L1 inhibitors.
Insights
Small-molecule inhibitors targeting PD-L1 offer a promising alternative to antibodies for cancer immunotherapy. Their structural scaffolds dictate efficacy by influencing protein interactions and immune modulation, guiding future drug development.
Area of Science:
- Oncology
- Immunology
- Medicinal Chemistry
Background:
- Cancer immunotherapy utilizes immune checkpoints like PD-1/PD-L1 and CTLA-4 to enhance anti-tumor responses.
- Monoclonal antibodies targeting PD-1/PD-L1 have advanced cancer treatment but present challenges like cost and toxicity.
- Small-molecule inhibitors are emerging as alternatives, aiming to overcome limitations of antibody-based therapies.
Purpose of the Study:
- To review the role of structural scaffolds in small-molecule PD-L1 inhibitors.
- To analyze how different chemotypes affect mechanism of action, protein interactions, and biological performance.
- To guide the design of next-generation small-molecule PD-L1 inhibitors for improved cancer treatment.
Main Methods:
- Review of existing literature on small-molecule PD-L1 inhibitors, focusing on structural aspects.
- Analysis of structure-activity relationships (SAR) and their impact on potency and selectivity.
- Comparison of scaffold design with in vitro, ex vivo, and in vivo model performance.
Main Results:
- Small-molecule PD-L1 inhibitor scaffolds influence PD-L1 dimerization, PD-1 binding disruption, and immune pathway engagement.
- Multifunctional scaffolds show potential for broader and more durable immunomodulatory effects.
- Physicochemical properties of scaffolds correlate with translatability and efficacy across different experimental systems.
Conclusions:
- Structural scaffold design is critical for the efficacy and mechanism of action of small-molecule PD-L1 inhibitors.
- Optimized scaffold design can lead to more effective and translatable cancer immunotherapies.
- Further research into novel scaffolds is essential for advancing small-molecule PD-L1 inhibitor development.
Related Concept Videos
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
02:04Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.